Recent Updates
Recently added Catalysts
SPRO Positive Sentiment

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Monday, May 5, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Spero Therapeutics will announce its first quarter 2025 financial results and provide a business update on May 13, 2025. The company, which specializes in treatments for rare diseases and multi-drug resistant infections, will release the information after market close. No conference call will follow the announcement.
Price reaction · baseline $0.647 (2025-05-02 close) · hit pre-market · clean, no other SPRO news in the window
day 0 close
-5.7%
day 1
-8.8%
day 3 · peak
-11.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Spero Therapeutics is focused on developing treatments for rare diseases.
  • The company is addressing multi-drug resistant bacterial infections.
  • The upcoming financial report indicates ongoing business activity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
7.4%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromide
Phase 1 · Renal Impairment

Full Press Release Details

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) --Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call.
AboutSperoTherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visitwww.sperotherapeutics.com

Investor Relations Contact:Shai Biran, PhDSpero TherapeuticsIR@Sperotherapeutics.comMedia Inquiries:media@sperotherapeutics.com

Frequently Asked Questions

When will Spero Therapeutics report its Q1 2025 results?

Spero Therapeutics will report its Q1 2025 financial results on May 13, 2025.

Will there be a conference call after the results?

No, Spero Therapeutics does not intend to host a conference call following the announcement.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for rare diseases and MDR bacterial infections.

Where is Spero Therapeutics headquartered?

Spero Therapeutics is headquartered in Cambridge, Massachusetts.

ShareAdd on Google
Tags: SPRO Viatris Investor Conferences Healthcare Spero Therapeutics financial results rare diseases MDR infections biopharmaceutical
Last updated: May 5, 2025

Biotech snapshot

Cash runway
$51M liquidity · $2M/mo burn
~28 mo
Minimal dilution risk
Lead asset
Tebipenem pivoxil hydrobromidePhase 1
Renal Impairment →

Catalyst track record

+8%
best trade around SPRO's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for SPRO.

See every catalyst's timing & PoA →